Last reviewed 2026-05-28 · How we verify

sévoflurane

Air Liquide Santé International · FDA-approved active Small molecule ✓ Verified May 2026 Quality 0/100

sévoflurane is a Small molecule drug developed by Air Liquide Santé International. It is currently FDA-approved.

Sévoflurane is a medication used to study hemodynamic stability and persistent postoperative pain in clinical trials. It has been compared to xenon in a clinical trial for hemodynamic stability during carotid endarterectomy.

At a glance

Generic name	sévoflurane
Sponsor	Air Liquide Santé International
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

sévoflurane CI brief — competitive landscape report
sévoflurane updates RSS · CI watch RSS
Air Liquide Santé International portfolio CI

Frequently asked questions about sévoflurane

What is sévoflurane?

sévoflurane is a Small molecule drug developed by Air Liquide Santé International.

Who makes sévoflurane?

sévoflurane is developed and marketed by Air Liquide Santé International (see full Air Liquide Santé International pipeline at /company/air-liquide-sant-international).

What development phase is sévoflurane in?

sévoflurane is FDA-approved (marketed).

Manufacturer: Air Liquide Santé International — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing